Peter Stebbins

Background

About Peter Stebbins

Entrepreneurial MedTech leader with a record of scaling businesses, large and small, Fortune 20 and scrappy start-up. Board Chair. Keen ability to swiftly understand a business, identify needs and opportunities, apply analytics, and steer organizations in strategy implementation. Currently applying broad expertise to steer small & mid-size companies and investors - deeply involved in Go to Market, Fund-raising, IP, M&A, KOLs, Branding, and US market entry. Both a Deal Guy and an Operator. End-to-end business acumen. “5-tool player.” Can galvanize cross-functional teams, partner with clinicians and inventors, and win market access. A connector and change agent who gets stuff done. Curated strategic advisory positions indexed toward digital: Augmented Reality (OnPoint), Enterprise SaaS Sales Targeting (AcuityMD), and Cloud-based Prior Authorizations (Voluware). Executive Chair of an Israeli biosurgery company (Nurami). Increasing strength in the Pharma<>Device intersection with Star Trek-like tele-injection program developed in partnership with Advanced Research Program Agency-Health (DARPA for Health). Record of Growing and Evolving Companies through a Variety of Skills: • STRATEGY and VISION Wrote strategy that became roadmap for Ethicon Biosurgery BU (now $1.4B from $70M). Built the first e-business strategy for JJMD across EMEA, 10 divisions and 20+ countries. • BEGINNING-TO-END DEAL MAKING By owning both strategy and L&A, drove synced-up process for M&A, License/Distribution deals, and Early Stage/VC Partnerships - from landscaping to target to deal and integration. • DRIVING COMMERCIAL BUSINESS GROWTH Played key role in growing Mitek from $100M to $650M through product launches, market creation, new market access capabilities, and deals. Led Codman portfolio into high growth Neurovascular (now Cerenovus BU). Revitalized SURGICEL hemostats portfolio as its first Product Director at Ethicon. • SUPPLY CHAIN AS STRATEGIC LEVER Executed a matrix of major programs including automation of suture manufacturing, product launches, and network optimization at Ethicon - reducing headcount by 1800 and saving $70m/year while re-establishing product superiority over US Surgical. Drove $1B+, 14 plant contract manufacturing collaboration. • PORTFOLIO MANAGEMENT - Carve-out DivesituresConsistently overachieved targets by crafting cohesive and compelling storylines. For example, sale of Advanced Sterilization Products for $2.8B (vs. WSJ estimate of $2.0B) and divestiture of Codman Instruments ($170M) without banker.